Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

DRAK2 anticorps (C-Term)

L’anticorps Lapin Polyclonal anti-DRAK2 a été validé pour WB, IF et IHC (p). Il convient pour détecter DRAK2 dans des échantillons de Humain et Souris. Il y a 3+ publications disponibles.
N° du produit ABIN1882073

Aperçu rapide pour DRAK2 anticorps (C-Term) (ABIN1882073)

Antigène

Voir toutes DRAK2 (STK17B) Anticorps
DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

Reactivité

  • 36
  • 15
  • 8
  • 1
  • 1
  • 1
Humain, Souris

Hôte

  • 33
  • 2
  • 1
Lapin

Clonalité

  • 35
  • 1
Polyclonal

Conjugué

  • 20
  • 3
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Cet anticorp DRAK2 est non-conjugé

Application

  • 24
  • 20
  • 8
  • 3
  • 3
  • 2
  • 2
Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone

RB3049
  • Épitope

    • 7
    • 6
    • 5
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 342-371, C-Term

    Purification

    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

    Immunogène

    This DRAK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 342-371 amino acids from the C-terminal region of human DRAK2.

    Isotype

    Ig Fraction
  • Indications d'application

    IF: 1:10~50. WB: 1:1000. IHC-P: 1:50~100

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

    Agent conservateur

    Sodium azide

    Précaution d'utilisation

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Stock

    4 °C,-20 °C

    Date de péremption

    6 months
  • Mao, Luo, Han, Bertrand, Wu: "Drak2 is upstream of p70S6 kinase: its implication in cytokine-induced islet apoptosis, diabetes, and islet transplantation." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 182, Issue 8, pp. 4762-70, (2009) (PubMed).

    Mao, Qiao, Luo, Wu: "Transgenic drak2 overexpression in mice leads to increased T cell apoptosis and compromised memory T cell development." dans: The Journal of biological chemistry, Vol. 281, Issue 18, pp. 12587-95, (2006) (PubMed).

    Sanjo, Kawai, Akira: "DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis." dans: The Journal of biological chemistry, Vol. 273, Issue 44, pp. 29066-71, (1998) (PubMed).

  • Antigène

    DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

    Autre désignation

    DRAK2

    Sujet

    DRAK2 is a novel serine/threonine kinase that induces apoptosis via catalytic activity. DRAKs present high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases. DRAK2 is located in nucleus, and the messenger RNA is ubiquitously expressed in human tissues.

    Poids moléculaire

    42344

    NCBI Accession

    NP_004217

    UniProt

    O94768
Vous êtes ici:
Chat with us!